RE: PDC's v ADC's22 Oct 2025 10:03
Reviews aren't really up to date articles as they report on reports of earlier work and are themselves some time in compilation, submission and acceptance. From a quick look, this one doesn't seem to cover conferences, which is a big omission. It also omits patents. Ouch! As Avacta's PDCs have only appeared in conference abstracts and patents (and even then as Bachovchin patents), then we are invisible to this review. It's also my impression that we've only recently started to emphasise the 'PDC' term.
The easiest way to get into a review is by publishing a peer-reviewed article with PDC or peptide drug conjugate in the title.